Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. Large recent multicentric randomised studies highlight the opportunities offered by a multiple treatment strategy in RAS wild-type metastatic colorectal cancer (mCRC). A review in the European Journal of Cancer [1] revealed that the optimal use and sequencing of cytotoxic chemotherapy and targeted agents across multiple lines of treatment for mCRC remain unclear.
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. Fig. 1 Schematic model of potential association between treatment duration, depth of response, progression-free survival and subsequent therapy in patients treated with FOLFIRI plus either cetuximab (Arm A) or bevacizumab (Arm B) in FIRE-3 [4,44,45] .
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
